XTL BIOPHARMACEUTICALS LTD (CIK: 0001023549) EDGAR, Information, Filings... CompaniesBIO.Com

XTL BIOPHARMACEUTICALS LTD

Mailing address
5 HACHAROSHET ST., RAANANA, Israel, 4365603
Phone
972 9 955 7080
State location
New York
State of incorporation
Israel
Fiscal year end
N/A
SIC
2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS
Filings
N/A

XTL BIOPHARMACEUTICALS LTD (CIK: 0001023549) is an American company incorporated in the state of New York. Head office is located at XTL BIOPHARMACEUTICALS LTD, C/O ALSTON & BIRD LLP, 90 PARK AVENUE, NEW YORK, New York, 10016. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. XTL BIOPHARMACEUTICALS LTD is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
ZUERBLIS KENNETH J	0001007923	Oct-10-2008	director
GOOD JENNIFER L	0001229245	Oct-10-2008	director
Rudman Samuel	0001448787	Oct-10-2008	director
WEINER BEN-ZION	0001444400	Aug-27-2008	director
WEISS MICHAEL S	0001038977	Aug-22-2008	director
EDELMAN JOSEPH	0001164426	Jan-03-2008	10 percent owner
PERCEPTIVE ADVISORS LLC	0001224962	Jan-03-2008	10 percent owner
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD	0001249675	Jan-03-2008	10 percent owner
Cho Michael	0001300949	Jan-03-2008	10 percent owner
Bradley Scott	0001410520	Jan-03-2008	10 percent owner
Kessler William	0001410538	Aug-21-2007	officer: Director of Finance
BENTSUR RON	0001251213	Aug-17-2006	officer: CEO
KENNEDY WILLIAM JAMES	0001448888	Aug-01-2005	director

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by XTL BIOPHARMACEUTICALS LTD

Filings	Format	Description	Filed/Effective	File/Film Number
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001013762-24-000446 (34 Act) Size: 17 KB	Jul-22-2024	001-36000 241131473
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-24-052080 (34 Act) Size: 2479 KB	Jun-12-2024	001-36000 241038395
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-24-049874 (34 Act) Size: 256 KB	Jun-05-2024	001-36000 241020948
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-24-042015 (34 Act) Size: 59 KB	May-13-2024	001-36000 24937422
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-24-037807 (34 Act) Size: 16 KB	Apr-30-2024	001-36000 24896975
20-F	Document	Annual and transition report of foreign private issuers pursuant to sections 13 or 15(d) Acc-no: 0001213900-24-037717 (34 Act) Size: 6451 KB	Apr-30-2024	001-36000 24896396
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-24-029320 (34 Act) Size: 9 KB	Apr-02-2024	001-36000 24814151
6-K/A	Document	Amendment to Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-24-024838 (34 Act) Size: 1356 KB	Mar-21-2024	001-36000 24772295
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-24-024787 (34 Act) Size: 1356 KB	Mar-21-2024	001-36000 24771858
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-24-024228 (34 Act) Size: 41 KB	Mar-20-2024	001-36000 24766624
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-23-087344 (34 Act) Size: 55 KB	Nov-15-2023	001-36000 231409387
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001013762-23-005431 (34 Act) Size: 31 KB	Oct-20-2023	001-36000 231337137
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-23-065316 (34 Act) Size: 47 KB	Aug-10-2023	001-36000 231157530
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-23-040240 (34 Act) Size: 58 KB	May-16-2023	001-36000 23926075
20-F	Document	Annual and transition report of foreign private issuers pursuant to sections 13 or 15(d) Acc-no: 0001213900-23-021869 (34 Act) Size: 5917 KB	Mar-22-2023	001-36000 23751449
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-23-016675 (34 Act) Size: 19 KB	Mar-02-2023	001-36000 23697934
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-23-013945 (34 Act) Size: 12 KB	Feb-23-2023	001-36000 23658914
6-K/A	Document	Amendment to Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-23-006569 (34 Act) Size: 422 KB	Feb-01-2023	001-36000 23575029
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-23-004144 (34 Act) Size: 445 KB	Jan-20-2023	001-36000 23541476
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-22-075760 (34 Act) Size: 50 KB	Nov-29-2022	001-36000 221429644

Recent 20 filings. View all XTL BIOPHARMACEUTICALS LTD filings

Overall rating 5.0

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

XTL BIOPHARMACEUTICALS LTD overview
XTL BIOPHARMACEUTICALS LTD job
XTL BIOPHARMACEUTICALS LTD stock
XTL BIOPHARMACEUTICALS LTD ownership
XTL BIOPHARMACEUTICALS LTD CEO
XTL BIOPHARMACEUTICALS LTD documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.